贝伐珠单抗联合化疗治疗转移性结直肠癌的近期效果及安全性  

Efficacy and safety of bevacizumab plus chemotherapy in treatment of patients with metastatic colorectal cancer

作　　者：张宁刚[1] 王育生[1] 张成琰[1] 李秀秀[1] 成翔宇[1] 温璐[1] 

机构地区：[1]山西省肿瘤医院消化一科,太原030013

出　　处：《肿瘤研究与临床》2014年第11期741-743,748,共4页Cancer Research and Clinic

基　　金：吴阶平医学基金（320.6750.12136）

摘　　要：目的 研究贝伐珠单抗（bevacizumab,Bev）联合化疗治疗转移性结直肠癌的近期疗效和安全性.方法 对43例接受贝伐珠单抗联合化疗治疗的晚期结直肠癌患者进行回顾分析,评价联合治疗的近期疗效及不良反应.结果 43例患者中部分缓解（PR）17例,疾病稳定（SD）19例,疾病进展（PD）7例;中位无进展生存（PFS）为10.3个月.3～4度不良反应主要为白细胞和粒细胞减少及恶心、呕吐.与贝伐珠单抗相关的不良反应为蛋白尿、高血压、鼻出血、经血增加、肠道出血、肠穿孔及静脉血栓等.结论 贝伐珠单抗联合化疗治疗晚期结直肠癌近期疗效较好,不良反应可耐受,远期疗效有待进一步观察.Objective To investigate the efficacy and safety of Bevacizumab （Bev） combined with chemotherapy protocols in the patients with metastatic colorectal cancer （mCRC）.Methods 43 patients with mCRC were treated with Bev combined with various of chemotherapy protocols.The efficacy was assessed based on Response Evaluation Criterion for Solid Tumors （RECIST）,and the adverse events were evaluated according to National Cancer Institute-Common Toxicity Criterion for Adverse Events （NCI-CTCAE） 3.0.Results The data of 43 patients （16 males and 27 females） were analyzed.17 patients achieved partial remission （PR）,19 patients stable disease （SD） and 7 patients progressive disease （PD）.The median progression-free survival （PFS） time was 10.3 months.The major of 3-4 adverse events included leucocytopenia,neutropenic febrile,and nausea/vomiting.Bey-associated adverse events were proteinuria,hypertension,rhinorrhagia,hemorrhagic hemorrhoid,menstrual blood increased,gastrointestinal perforation and venous thrombosis.Conclusions Bey combined with various chemotherapy protocols is more effective for patients with mCRC.Most patients can tolerate the side effects of the combined treatment.The long-term effects of the combined treatment need to be followed up.

关 键 词：结肠肿瘤 直肠肿瘤 分子靶向治疗 贝伐珠单抗 抗肿瘤联合化疗方案 

分 类 号：R735.34[医药卫生—肿瘤]